Polyinosinic-polycytidylic Acid Improved As An Adjuvant In Rabies Vaccine For Human Use

Rabies is one of the highest lethality infectious diseases, a serious threat to people's lives. Vaccination is one of the most effective ways to prevention of rabies. But the result that used the current vaccine is unsatisfactory. Therefore, the development of safer and more efficient rabies vaccine is the focus of pharmaceutical research.Polyinosinic-polycytidylic acid injection shall be concentrated by means of 100000 dalton membrane packages ultration to wipe off small molecular Polyinosinic-polycytidylic acid. Adjustment of Polyinosinic-polycytidylic acid improved concentration shall be carried out according to its content; its final concentration shall be 2.0mg/ml. And its molecular is between 300000 to 550000 dalton; the Polyinosinic-polycytidylic acid injection improved complies with the test for hyperchromic effect.The Polyinosinic-polycytidylic acid improved (2.0mg/ml) and the original as a diluent add to Rabies Vaccine for Human Use. Compared the Polyinosinic-polycytidylic acid improved as a diluent add to Rabies Vaccine for Human Use with the original, The experimental results show that the rabies vaccine potency increase of between 1.4 to 2.3 IU/dose; the level of Induced formation Mouse serum interferon increase of 6 times; the effect of promoting cellular immune function and a increase in mouse neutralizing antibody is a visible fact; guinea pigs without active systemic allergic reaction. So the study proved effect of the Polyinosinic-polycytidylic acid improved as an Adjuvant add to Rabies Vaccine for Human Use.